The impact of <scp> <i>JAK2</i> <sup>V617F</sup> </scp> variant allele frequency in <scp>MPN</scp> patients following <scp>PEGylated</scp> interferon alpha discontinuation
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2<sup>V61F</sup> VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2<sup>V617F</sup> VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).
Authors
- Graeme Greenfield (ORCID: https://orcid.org/0000-0003-2333-1374)
- Clare M. Crean
- Ciaren Graham (ORCID: https://orcid.org/0000-0003-1851-7369)
- Nicholas Cunningham (ORCID: https://orcid.org/0009-0001-3863-2439)
- Aaron Niblock (ORCID: https://orcid.org/0000-0001-9454-2692)
- Suzanne McPherson (ORCID: https://orcid.org/0000-0003-1150-5357)
- Mary Frances McMullin
- Allister Foy (ORCID: https://orcid.org/0000-0003-3248-9894)
- Ryan Brown
- Kathryn Boyd (ORCID: https://orcid.org/0000-0001-6290-8020)
- Rebekah Russell‐Bennett (ORCID: https://orcid.org/0000-0002-9782-2427)
- Andrew Hindley
- Mark Catherwood (ORCID: https://orcid.org/0000-0001-8219-4651)
- Julie McGimpsey
Institutions
- Queen's University Belfast (GB)
- Belfast Health and Social Care Trust (GB)
- Northern Health and Social Care Trust (GB)
- Queens University (BD)
- Southern Health and Social Care Trust (GB)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1111/bjh.70198
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00